Eli Lilly posts full trial data for obesity pill (LLY:NYSE)

seekingalpha.com/news/4495588-eli-lilly-posts-full-trial-data-obesity-pill

Eli Lilly (NYSE:LLY) on Wednesday posted detailed data from its ATTAIN-1 Phase 3 trial for its oral GLP-1 receptor agonist, orforglipron as presented at a European medical event and simultaneously published in The New England Journal of Medicine.
Shares of

This story appeared on seekingalpha.com, 2025-09-17 15:34:36.820000.
The Entire Business World on a Single Page. Free to Use →